First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
Our site participated in this study, where patients were tested for ESR1 mutations via circulating tumor DNA (ctDNA). Those who tested positive were switched to camizestrant (Cami), which demonstrated improved progression-free survival.